Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (MiMe-A)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03339843
Recruitment Status : Recruiting
First Posted : November 13, 2017
Last Update Posted : June 24, 2019
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Jules Bordet Institute

Brief Summary:

Open-label, phase II, basket trial. This trial is a screening program for abemaciclib efficacy in multiple platinum-resistant tumour types by using metabolic imaging (PERCIST) and RECIST v1.1 criteria.

Based on the rate of FDG-avidity and the absence of deactivation of the Rb gene function in more than 95% of cases, we propose to define 5 tumour types of interest in a preliminary stage:

  1. Platinum-refractory esophageal adenocarcinoma (ADC)
  2. Platinum-refractory esophageal squamous cell carcinoma (SCC)
  3. Platinum-refractory cholangiocarcinoma
  4. Platinum-refractory and progressive after immunotherapy urothelial cancer
  5. Platinum-refractory endometrial cancer

Condition or disease Intervention/treatment Phase
Esophageal Adenocarcinoma Esophagus SCC Cholangiocarcinoma Urothelial/Bladder Cancer, Nos Endometrial Cancer Drug: Abemaciclib Phase 2

Detailed Description:

In various solid tumour types FDG-PET/CT has been shown to identify treatment-refractory diseases with a high negative predictive value (NPV) through a whole-body quantitative assessment of treatment-induced changes in tumour glucose uptake soon after treatment initiation, before any structural changes are observed. Progress in the standardisation of FDG-PET/CT imaging and response analysis now allow its use in multicentric trials opening the possibilities for trials where treatment allocation will be based on early metabolic response. MiMe has been built on the assumption that a medication which does not induce any metabolic changes in a given clinical setting is unlikely to induce a significant benefit and does consequently not deserve further investigation as a single agent in this setting.

MiMe, by assessing metabolic response early during the treatment course, will hopefully provide useful information about the drug activity in various cancer types, and about mechanisms of resistance through a potential ambitious translational research program with serial collection of circulating-tumour DNA (ct-DNA).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 85 participants
Intervention Model: Sequential Assignment
Intervention Model Description: This is a two step, open-label, basket trial looking at 5 different tumour types.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Actual Study Start Date : December 19, 2018
Estimated Primary Completion Date : October 15, 2021
Estimated Study Completion Date : October 15, 2021


Arm Intervention/treatment
Experimental: Abemaciclib

This study contains 2 stages; during the 1st stage, a maximum of 17 patients will be enrolled in each tumour type cohort. After 13 evaluable patients have been enrolled, an interim analysis will be performed. If 3 or more patients are seen to have experienced a treatment success, then the cohort will pass into the 2nd stage in which a maximum of 20 more patients are enrolled. If 2 or less patients are seen to have experienced a treatment success, then that cohort will be closed and will not proceed into the 2nd stage.

Subjects will receive 200 mg of abemaciclib orally, twice a day, during cycles of 28 days each. The subject will undergo: A baseline FDG-PET/CT and a baseline CT scan and A blinded early FDG-PET/CT at D14 +/- 2 days of study treatment.

A treatment success is defined as a patient who has metabolic response according to PERCIST with a response cut off set at 15% at the early FDG-PET/CT and a morphological disease control after 2 cycles measured by RECIST v1.1.

Drug: Abemaciclib
Subjects will receive 200 mg of abemaciclib orally, two times a day, during cycles of 28 days each. An early FDG-PET/CT will be performed at cycle 1 day 14 to search for any new lesions.
Other Name: FDG-PET/CT




Primary Outcome Measures :
  1. Evaluate the anti-tumour activity of abemaciclib in the five tumour types studied in this trial using FDG-PET/CT during the first cycle of therapy (early FDG- PET/CT). [ Time Frame: 2 months ]
    Therapy success rate defined as: PERCIST 15%-assessed Metabolic Response at early FDG-PET/CT (D12-D16)

  2. Evaluate the anti-tumour activity of abemaciclib in the five tumour types studied in this trial using RECISTv1.1 after 2 cycles of therapy as a screening tool. [ Time Frame: 2 Months ]
    Therapy success rate defined as: RECISTv1.1-assessed Disease Control (DC) after 2 treatment cycles (CR or PR or SD)


Secondary Outcome Measures :
  1. Evaluate Progression-free survival (PFS define as the time from treatment start until disease progression or death) at 24 weeks from treatment start [ Time Frame: 6 months ]
    RECIST v1.1-based radiological response assessment performed at 24 weeks from the treatment start to determine the PFS

  2. Evaluate Overall Survival (OS defined as the time from treatment start until death) at 24 weeks from treatment start [ Time Frame: 6 months ]
    RECIST v1.1-based radiological response assessment performed at 24 weeks from the treatment start to determine the OS.

  3. To evaluate median progression-free survival (PFS) [ Time Frame: 42 months ]
    Progression Free Survival

  4. Evaluate median overall survival (OS) [ Time Frame: 42 months ]
    Overall Survival

  5. To evaluate toxicity profile [ Time Frame: 6 months ]
    Toxicity profile according to CTCAE version 4.03

  6. Evaluate the correlation of early metabolic response using FDG-PET/CT with morphological response to treatment assessed by RECIST [ Time Frame: 6 months ]
    RECIST v1.1-based radiological response assessment performed at 24 weeks from the treatment start to determine the PFS and OS



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years old
  2. Female or male
  3. ECOG performance status ≤ 1
  4. Life expectancy of greater than 12 weeks
  5. Must have histologically confirmed cancer corresponding to the predefined tumour subtypes (esophageal adenocarcinoma, esophageal squamous cell carcinoma, cholangiocarcinoma, urothelial cancer (progressive after immunotherapy), endometrial cancer) and metastatic or non-resectable and refractory to standard platinum regimens (and progressive after immunotherapy for the urothelial cancer).
  6. Presence of at least one metabolically measurable tumour lesion on FDG-PET/CT, according to PERCIST. If previously irradiated, must have been more than 2 months before the baseline FDG PET/CT.
  7. Measurable disease according to RECIST v 1.1
  8. Serum pregnancy test (for subjects of childbearing potential) negative
  9. Women of childbearing potential must agree to the use a highly effective method of contraception prior to study entry, during the course of the study and at least 3 months after the last administration of study treatment.
  10. Men with childbearing potential partner must agree to use condom during the course of this study and for at least 3 months after the last administration of the study treatment.
  11. Adequate coagulation: International Normalized Ratio (INR) ≤ 1.5 x ULN unless subject is receiving anticoagulant therapy as long as INR and activated partial thromboplastin time [aPTT] are within therapeutic range of intended use of anticoagulants
  12. Adequate bone marrow function as defined below:

    • Hemoglobin ≥ 10 g/dL
    • Absolute neutrophil count ≥ 1500/µL or 1.5x109/L
    • Platelets ≥ 100000/µL or 100x109/L
    • Leukocytes ≥ 3,000/µL
  13. Adequate liver function as defined below:

    • Serum total bilirubin within 1.5 × normal institutional limits (except for Gilbert syndrome where direct bilirubin should be <1.5 institutional ULN)
    • AST/ALT/ALP) levels < 3 × institutional upper limit of normal (or ALT and AST <5 times upper limit of normal if liver metastases are present).
  14. Adequate renal function as defined below: Cockcroft-Gault creatine clearance >50ml/min
  15. Completion of all necessary screening procedures
  16. Ability to swallow capsules
  17. Grade ≤ 1 toxicity due to any previous cancer therapy according to the National Cancer Institute Common Terminology Criteria of Adverse Events (NCI-CTCAE, v.4.03). Grade 2 is allowed in case of alopecia and peripheral sensory neuropathy
  18. Availability of primary archived tumour tissue block (1 FFPE tumour tissue)
  19. Signed Informed Consent form (ICF) obtained prior to any study related procedure

Exclusion Criteria:

  1. Subjects meeting one of the following criteria are not eligible for this studyParticipants who have had chemotherapy, radiotherapy, immunotherapy, or targeted therapy within 3 weeks prior study enrolment
  2. Participants receiving concomitantly any other experimental agents
  3. Patients who have received prior therapy with other CDK4/6 inhibitors
  4. Subjects with known brain metastasis; unless the metastasis are asymptomatic and have been stable since at least 2 months prior to treatment start.
  5. Patient with meningeal carcinomatosis
  6. Have had major surgery within 28 days prior to the start of the treatment to allow for post-operative healing of the surgical wound
  7. History of allergic reactions attributed to compounds of similar chemical or biologic composition
  8. Bleeding diathesis, thromboembolic event, history of cardiovascular ischemic disease or cerebrovascular incident within the last six months
  9. Uncontrolled concurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia
  10. Substance abuse, psychiatric illness/social situations, any psychological, familial, sociological, geographical condition, significant medical or surgical condition currently uncontrolled by treatment that would limit compliance with study requirements or interfere with the patient's ability to understand informed consent and participation in the study
  11. Pregnant and/or lactating women
  12. Uncontrolled Diabetes
  13. Known history of HIV infection, or active hepatitis B or C requiring treatment with anti-viral therapy
  14. Have received recent (within 28 days prior the enrolment) yellow fever vaccination
  15. Individuals with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free and are deemed by the investigator to be at low risk for recurrence of that malignancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03339843


Contacts
Layout table for location contacts
Contact: Laura Polastro, MD +3225413279 laura.polastro@bordet.be

Locations
Layout table for location information
Belgium
Universitair Ziekenhuis Not yet recruiting
Antwerpen, Belgium
Contact: Hans Prenen, MD         
Institut Jules Bordet Recruiting
Bruxelles, Belgium, 1000
Contact: Alain Hendlisz, MD         
Algemeen Ziekenhuis Groeninge Recruiting
Kortrijk, Belgium, 8500
Contact: Philippe Vergauwe, MD         
CHC Saint-Joseph Recruiting
Liège, Belgium, 4000
Contact: Gauthier Demolin, MD         
CHU Ambroise Paré Recruiting
Mons, Belgium, 7000
Contact: Stephane Holbrechts, MD         
CHU UCL Namur Sainte-Elisabeth Recruiting
Namur, Belgium, 5000
Contact: Peter Vuylsteke, MD         
Sponsors and Collaborators
Jules Bordet Institute
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Chair: Laura Polastro, MD Jules Bordet Institute

Layout table for additonal information
Responsible Party: Jules Bordet Institute
ClinicalTrials.gov Identifier: NCT03339843     History of Changes
Other Study ID Numbers: IJB-MULTI-MIME-A-2017
First Posted: November 13, 2017    Key Record Dates
Last Update Posted: June 24, 2019
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Jules Bordet Institute:
cancer

Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Endometrial Neoplasms
Cholangiocarcinoma
Esophageal Neoplasms
Neoplasms
Urologic Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Urogenital Neoplasms
Neoplasms by Site
Uterine Neoplasms
Genital Neoplasms, Female
Gastrointestinal Neoplasms
Digestive System Neoplasms
Head and Neck Neoplasms
Adenocarcinoma
Carcinoma
Urinary Bladder Diseases
Urologic Diseases
Uterine Diseases
Genital Diseases, Female
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases